Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 397267, 8 pages
http://dx.doi.org/10.1155/2012/397267
Review Article

Immunotherapy of Genitourinary Malignancies

Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan

Received 8 October 2011; Accepted 26 December 2011

Academic Editor: M. Roach

Copyright © 2012 Teruo Inamoto and Haruhito Azuma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. Naito, N. Yamamoto, T. Takayama et al., “Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients,” European Urology, vol. 57, no. 2, pp. 317–326, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. Pizza, C. De Vinci, G. L. Conte et al., “Immunotherapy of metastatic kidney cancer,” International Journal of Cancer, vol. 94, no. 1, pp. 109–120, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. M. Donat, E. W. Salzhauer, N. Mitra, B. V. Yanke, M. E. Snyder, and P. Russo, “Impact of body mass index on survival of patients with surgically treated renal cell carcinoma,” Journal of Urology, vol. 175, no. 1, pp. 46–52, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. A. Moyad, “Obesity, interrelated mechanisms, and exposures and kidney cancer,” Seminars in Urologic Oncology, vol. 19, no. 4, pp. 270–279, 2001. View at Google Scholar · View at Scopus
  6. J. Arends, “Metabolism in cancer patients,” Anticancer Research, vol. 30, no. 5, pp. 1863–1868, 2010. View at Google Scholar · View at Scopus
  7. F. Bauer, C. C. Elbers, R. A. H. Adan et al., “Obesity genes identified in genome-wide association studies are associated with adiposity measures and potentially with nutrient-specific food preference,” The American Journal of Clinical Nutrition, vol. 90, no. 4, pp. 951–959, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. S. Bingham, R. Luben, A. Welch, N. Tasevska, N. Wareham, and K. T. Khaw, “Epidemiologic assessment of sugars consumption using biomarkers: comparisons of obese and nonobese individuals in the European prospective investigation of cancer Norfolk,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 8, pp. 1651–1654, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. Civera, A. Urios, M. L. Garcia-Torres et al., “Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 3, pp. 187–192, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. García-Lafuente, E. Guillamón, A. Villares, M. A. Rostagno, and J. A. Martínez, “Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease,” Inflammation Research, vol. 58, no. 9, pp. 537–552, 2009. View at Publisher · View at Google Scholar · View at PubMed
  11. J. O. Rosado, M. Salvador, and D. Bonatto, “Importance of the trans-sulfuration pathway in cancer prevention and promotion,” Molecular and Cellular Biochemistry, vol. 301, no. 1-2, pp. 1–12, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. W. Lee, G. H. Park, S. Y. Lee, J. H. Song, and M. J. Kim, “Comparison of anthropometric data between end-stage renal disease patients undergoing hemodialysis and healthy adults in Korea,” Yonsei Medical Journal, vol. 46, no. 5, pp. 658–666, 2005. View at Google Scholar · View at Scopus
  13. M. Navarro-Díaz, A. Serra, D. López, M. Granada, B. Bayés, and R. Romero, “Obesity, inflammation, and kidney disease,” Kidney International, vol. 74, no. S111, pp. S15–S18, 2008. View at Publisher · View at Google Scholar · View at PubMed
  14. A. J. Zurita, E. Jonasch, X. Wang et al., “A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma,” Annals of Oncology, vol. 23, no. 1, pp. 46–52, 2012. View at Publisher · View at Google Scholar · View at PubMed
  15. Z. Zhu, S. Zhong, and Z. Shen, “Targeting the inflammatory pathways to enhance chemotherapy of cancer,” Cancer Biology & Therapy, vol. 12, no. 2, pp. 95–105, 2011. View at Publisher · View at Google Scholar
  16. X. Zhang, X. Shi, J. Li et al., “Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells,” Urology, vol. 78, no. 3, pp. 722.e1–722.e6, 2011. View at Publisher · View at Google Scholar · View at PubMed
  17. H. M. Zarour and S. Ferrone, “Cancer immunotherapy: progress and challenges in the clinical setting,” European Journal of Immunology, vol. 41, no. 6, pp. 1510–1515, 2011. View at Publisher · View at Google Scholar · View at PubMed
  18. D. R. Yates and M. Rouprêt, “Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy,” World Journal of Urology, vol. 29, no. 4, pp. 415–422, 2011. View at Publisher · View at Google Scholar · View at PubMed
  19. T. N. Spyridopoulos, E. T. Petridou, N. Dessypris et al., “Inverse association of leptin levels with renal cell carcinoma: results from a case-control study,” Hormones, vol. 8, no. 1, pp. 39–46, 2009. View at Google Scholar · View at Scopus
  20. H. A. Drabkin and R. M. Gemmill, “Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC),” Advances in Cancer Research, vol. 107, pp. 39–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. S. Martin, A. Qasim, and M. P. Reilly, “Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease,” Journal of the American College of Cardiology, vol. 52, no. 15, pp. 1201–1210, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. Johnston, S. Arnadottir, J. E. Gudjonsson et al., “Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation,” British Journal of Dermatology, vol. 159, no. 2, pp. 342–350, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. X. Hu, S. C. Juneja, N. J. Maihle, and M. P. Cleary, “Leptin—a growth factor in normal and malignant breast cells and for normal mammary gland development,” Journal of the National Cancer Institute, vol. 94, no. 22, pp. 1704–1711, 2002. View at Google Scholar · View at Scopus
  24. M. S. Hickey, R. V. Considine, R. G. Israel et al., “Leptin is related to body fat content in male distance runners,” American Journal of Physiology, vol. 271, no. 5, part 1, pp. E938–E940, 1996. View at Google Scholar · View at Scopus
  25. K. K. Kumar, S. Tung, and J. Iqbal, “Bone loss in anorexia nervosa: leptin, serotonin, and the sympathetic nervous system,” Annals of the New York Academy of Sciences, vol. 1211, pp. 51–65, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. F. Mulder, J. F. M. Jacobs, M. A. M. Olde Nordkamp et al., “Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination,” Clinical Cancer Research, vol. 17, no. 13, pp. 4541–4549, 2011. View at Publisher · View at Google Scholar · View at PubMed
  27. M. Ahmadzadeh and S. A. Rosenberg, “IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients,” Blood, vol. 107, no. 6, pp. 2409–2414, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. C. Coppin, “Immunotherapy for renal cell cancer in the era of targeted therapy,” Expert Review of Anticancer Therapy, vol. 8, no. 6, pp. 907–919, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. R. Passalacqua, C. Buzio, S. Buti et al., “Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer,” Cancer Immunology, Immunotherapy, vol. 59, no. 4, pp. 553–561, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. K. Margolin, T. W. Synold, P. Lara et al., “Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium,” Journal of Cancer Research and Clinical Oncology, vol. 133, no. 10, pp. 705–711, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. A. Garcia, T. Mekhail, P. Elson et al., “Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma,” BJU International, vol. 109, no. 1, pp. 63–69, 2012. View at Publisher · View at Google Scholar · View at PubMed
  32. K. D. Somers, R. R. Brown, D. A. Holterman et al., “Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy,” International Journal of Cancer, vol. 107, no. 5, pp. 773–780, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. E. Morelli, P. T. H. Coates, W. J. Shufesky et al., “Growth factor-induced mobilization of dendritic cells in kidney and liver of rhesus macaques: implications for transplantation,” Transplantation, vol. 83, no. 5, pp. 656–662, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. E. Lierman, I. Lahortiga, H. Van Miegroet, N. Mentens, P. Marynen, and J. Cools, “The ability of sorafenib to inhibit oncogenic PDGFRβ and FLT3 mutants and overcome resistance to other small molecule inhibitors,” Haematologica, vol. 92, no. 1, pp. 27–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. D. J. Schendel, B. Frankenberger, P. Jantzer et al., “Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse,” Gene Therapy, vol. 7, no. 23, pp. 2007–2014, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. F. M. Lemoine, M. Cherai, C. Giverne et al., “Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer,” International Journal of Oncology, vol. 35, no. 3, pp. 569–581, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. D. C. Cho, I. Puzanov, M. M. Regan et al., “Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma,” Journal of Immunotherapy, vol. 32, no. 2, pp. 181–185, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. A. Gollob, W. K. Rathmell, T. M. Richmond et al., “Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3288–3295, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. A. Boorjian, F. Zhu, and H. W. Herr, “The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder,” BJU International, vol. 106, no. 3, pp. 357–361, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. M. Babjuk, W. Oosterlinck, R. Sylvester et al., “EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update,” European Urology, vol. 59, no. 6, pp. 997–1008, 2011. View at Publisher · View at Google Scholar · View at PubMed
  41. A. Stenzl, N. C. Cowan, M. De Santis et al., “The updated EAU guidelines on muscle-invasive and metastatic bladder cancer,” European Urology, vol. 55, no. 4, pp. 815–825, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. M. C. Hall, S. S. Chang, G. Dalbagni et al., “Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update,” Journal of Urology, vol. 178, no. 6, pp. 2314–2330, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. T. L. Ratliffe, L. R. Kavoussi, and W. J. Catalona, “Role of fibronectin in intravesical BCG therapy for superficial bladder cancer,” Journal of Urology, vol. 139, no. 2, pp. 410–414, 1988. View at Google Scholar · View at Scopus
  44. D. C. Chade, R. C. Borra, I. P. Nascimento et al., “Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model,” Journal of Experimental and Clinical Cancer Research, vol. 27, no. 1, article 78, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. D. L. Lamm, B. A. Blumenstein, J. D. Crissman et al., “Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study,” Journal of Urology, vol. 163, no. 4, pp. 1124–1129, 2000. View at Google Scholar · View at Scopus
  46. M. M. Wishahi, I. M. H. Ismail, and M. El-Sherbini, “Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis,” British Journal of Urology, vol. 73, no. 6, pp. 649–654, 1994. View at Google Scholar · View at Scopus
  47. D. L. Lamm, A. P. M. van der Meijden, A. Morales et al., “Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer,” Journal of Urology, vol. 147, no. 3, pp. 596–600, 1992. View at Google Scholar · View at Scopus
  48. D. Mack and J. Frick, “Low-dose bacille Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada,” British Journal of Urology, vol. 75, no. 2, pp. 185–187, 1995. View at Google Scholar · View at Scopus
  49. S. Mugiya, S. Ozono, M. Nagata et al., “Long-term outcome of a low-dose intravesical bacillus Calmette-Guérin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG,” Japanese Journal of Clinical Oncology, vol. 35, no. 7, pp. 395–399, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. W. P. J. Witjes, J. A. Witjes, G. O. N. Oosterhof, and F. M. J. Debruyne, “Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group,” Seminars in Urologic Oncology, vol. 14, no. 1, supplement 1, pp. 10–16, 1996. View at Google Scholar
  51. A. Losa, R. Hurle, and A. Lembo, “Low dose bacillus Calmette-Guérin for carcinoma in situ of the bladder: long-term results,” Journal of Urology, vol. 163, no. 1, pp. 68–72, 2000. View at Google Scholar · View at Scopus
  52. F. Pagano, P. Bassi, N. Piazza, G. Abatangelo, G. L. Drago Ferrante, and C. Milani, “Improving the efficacy of BCG immunotherapy by dose reduction,” European Urology, vol. 27, supplement 1, pp. 19–22, 1995. View at Google Scholar · View at Scopus
  53. F. Pagano, P. Bassi, C. Milani, A. Meneghini, D. Maruzzi, and A. Garbeglio, “A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective?” Journal of Urology, vol. 146, no. 1, pp. 32–35, 1991. View at Google Scholar · View at Scopus
  54. D. L. Lamm, “Optimal BCG treatment of superficial bladder cancer as defined by American trials,” European Urology, vol. 21, supplement 2, pp. 12–16, 1992. View at Google Scholar · View at Scopus
  55. A. Irie, T. Uchida, H. Yamashita et al., “Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence,” International Journal of Urology, vol. 10, no. 4, pp. 183–189, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Takashi, K. Wakai, Y. Ohno, T. Murase, and K. Miyake, “Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer,” International Urology and Nephrology, vol. 27, no. 6, pp. 723–733, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. A. I. Kamel, A. G. El Baz, W. T. Abdel Salam, M. E. El Din Ryad, and A. A. Mahena, “Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term results,” Journal of the Egyptian National Cancer Institute, vol. 21, no. 2, pp. 151–155, 2009. View at Google Scholar
  58. R. Hurle, A. Losa, A. Ranieri, P. Graziotti, and A. Lembo, “Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy,” Journal of Urology, vol. 156, no. 5, pp. 1602–1605, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. H. W. Herr, D. M. Schwalb, Z. F. Zhang et al., “Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial,” Journal of Clinical Oncology, vol. 13, no. 6, pp. 1404–1408, 1995. View at Google Scholar · View at Scopus
  60. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. G. Sonpavde, N. Agarwal, T. K. Choueiri, and P. W. Kantoff, “Recent advances in immunotherapy for the treatment of prostate cancer,” Expert Opinion on Biological Therapy, vol. 11, no. 8, pp. 997–1009, 2011. View at Publisher · View at Google Scholar · View at PubMed
  63. E. J. Small, P. F. Schellhammer, C. S. Higano et al., “Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3089–3094, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus